PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
12108896-4	2002	A trial conducted in the United Kingdom demonstrated that docetaxel sequential to CVAP (cyclophosphamide [Cytoxan, Neosar], vincristine, doxorubicin [Adriamycin], prednisolone) produced a higher overall clinical response rate (94% vs 66%, P = .001) and pathologic complete response rate (34% vs 18%) compared to additional cycles of CVAP as primary chemotherapy.	Docetaxel	58-67	amyloid beta precursor protein	Homo sapiens	333-337	
12868802-14	2003	The addition of docetaxel improved overall survival and disease-free survival for patients responding to four cycles of CVAP as compared with those receiving eight cycles of CVAP.	Docetaxel	16-25	amyloid beta precursor protein	Homo sapiens	120-124	
11346684-4	2001	Further, patients with an initial clinical response to CVAP were more likely to show a pathological complete response (pCR) at final assessment when four cycles of CVAP were followed by four of docetaxel than when CVAP was maintained for eight cycles (pCR rate 34% versus 16%).	Docetaxel	194-203	amyloid beta precursor protein	Homo sapiens	55-59	
16622435-9	2006	Neoadjuvant docetaxel-cisplatin was effective and tolerable in stage IIIA pN2 NSCLC, with chemotherapy contributing significantly to outcomes.	Docetaxel	12-21	amyloid beta precursor protein	Homo sapiens	74-77	
12721251-11	2003	CONCLUSION: Neoadjuvant docetaxel-cisplatin is effective and tolerable in stage IIIA pN2 NSCLC.	Docetaxel	24-33	amyloid beta precursor protein	Homo sapiens	85-88	
12435290-5	2002	It was shown that the addition of sequential docetaxel (100 mg/m2) to CVAP neoadjuvant chemotherapy resulted in a significantly enhanced clinical response rate (94% vs. 64%) and a substantially increased complete histopathological response rate (34% vs. 16%) when compared to patients receiving CVAP alone.	Docetaxel	45-54	amyloid beta precursor protein	Homo sapiens	295-299